KR970701776A - 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) - Google Patents
형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1)Info
- Publication number
- KR970701776A KR970701776A KR1019960704894A KR19960704894A KR970701776A KR 970701776 A KR970701776 A KR 970701776A KR 1019960704894 A KR1019960704894 A KR 1019960704894A KR 19960704894 A KR19960704894 A KR 19960704894A KR 970701776 A KR970701776 A KR 970701776A
- Authority
- KR
- South Korea
- Prior art keywords
- tgf
- polypeptide
- polynucleotide
- dna
- encoding
- Prior art date
Links
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 title 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 title 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- 229920001184 polypeptide Polymers 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract 5
- 239000005557 antagonist Substances 0.000 claims abstract 4
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 239000002299 complementary DNA Substances 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims 14
- 102000040430 polynucleotide Human genes 0.000 claims 14
- 239000002157 polynucleotide Substances 0.000 claims 14
- 108020004414 DNA Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 사람 TGFα-H1 폴리펩타이드와 이와 같은 TGFα-H1 폴리펩타이드를 암호화 하는 DNA(RNA)에 관한 것이다. 또한 본 발명은 재조합 기술에 의해 폴리펩타이드를 제조하고 이와 같은 폴리펩타이드에 대한 향체 및 길항체를 제조하는 방법에 관한 것이다. 이와 같은 폴리펩타이드는 적합한 약제학적 담체 또는 희석제와 배합되어 각종 질병에 대한 진단 효과, 치료 효과 및/또는 예방 효과를 제공할수 있다. 또한 본 발명은 치료학적 목적으로 TGFα-H1을 억제하기 위해 항체와 길항제를 사용하는 방법에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 TGFα-H1 cDNA의 개방 판독 프레임의 예견된 아미노산 해독을 나타낸다.
제2도는 3,286개 뉴클레오타이드를 가진 TGFα-H1 cDNA의 완전한 뉴클레오타이드 서열을 나타낸다.
제3도는 TGFα-H1과 TGFα유전자과의 다른 구성원의 정렬을 나타낸다.
제4도는 본 발명의 폴리펩타이드의 RNA 발현 패턴을 나타내는 노던 블롯 분석의 결과를 나타낸다.
Claims (23)
- 제1도는 유추된 아미노산 서열을 지닌 TGFα-H1폴리펩타이드 또는 이러한 폴리펩타이드의 활성 단편, 동족체 또는 유도체를 암호화하는 폴리뉴클레오타이드(a ) 및 ATCC 기탁 번호 제75698호에 포함된 cDNA가 암호화하는 아미노산 서열을 지닌 TGFα-H1폴리펩타이드 또는 이러한 폴리펩타이드의 활성 단편, 동족체 또는 유도체를 암호화 하는 폴리뉴클레오타이드(b)로 이루어진 그룹으로부터 선택된, TGFα-H1을 암호화 하는 분리된 폴리뉴클레오타이드.
- 제1항에 있어서, DNA인 폴리뉴클레오타이드.
- 제1항에 있어서, TGFα-H1의 가용성 단편을 암호화하는 폴리뉴클레오타이드.
- 제1항에 있어서, RNA인 폴리뉴클레오타이드.
- 제1항에 있어서, 게놈성 DNA인 폴리뉴클레오타이드.
- 제2항에 있어서, 제1도의 유추된 아미노산 서열을 지닌 TGFα-H1을 암호화하는 폴리뉴클레오타이드.
- 제2항에 있어서, ATCC 기탁 번호 제 75698호의 cDNA가 암호화하는 TGFα-H1폴리펩타이드를 암호화하는 폴리뉴클레오타이드.
- 제1항에 있어서,제1도의 TGFα-H1에 대한 암호화 서열을 지닌 폴리뉴클레오타이드.
- 제2항에 있어서, ATCC 기탁 번호 제75698호의 로써의 기탁된 TGFα-H1에 대한 암호화 서열을 지닌 폴리뉴클레오타이드.
- 제2항에 따른 DNA를 포함하는 벡터.
- 제10항의 벡터로 유전적 처리된 숙주 세포.
- 제11항에 따르는 숙주 세포로부터 DNA가 암호화하는 폴리펩타이드를 발현시킴을 포함하는, 폴리펩타이드의 생산방법.
- 제10항에 따르는 벡터로 세포를 유전적 처리함을 포함하는, 폴리펩타이드를 발현할 수 있는 세포의 생산 방법.
- 제2항에 따른 DNA에 하이브리드화할 수 있고 TGFα-H1 활성을 지닌 폴리뉴클레오타이드를 암호화 하는 분리된 DNA.
- 제1도의 유추된 아미노산 서열을 지닌TGFα-H1폴리펩타이드와 이의 활성 단편, 동족체 및 유도체를 지닌 TGFα-H1폴리펩타이드(i) 및 ATCC 기탁 번호 제 75698호의 cDNA가 암호화한 TGFα-H1폴리펩타이드와 이러한 폴리펩타이드의 활성 단편, 동족체 및 유도체 (ii)로 이루어진 그룹으로부터 선택된 폴리펩타이드.
- 제15항에 있어서, 제1도의 유추된 아미노산 서열을 지닌TGFα-H1인 폴리펩타이드.
- 제15항에 따르는 폴리펩타이드에 대한 항체.
- 제15항에 따르는 폴리펩타이드에 대한 길항체/억제제.
- TGFα-H1을 필요로 하는 환자에게 제15항에 따르는 폴리펩타이드의 치료학적 유효량을 투여함을 포함하는, TGFα-H1을 필요로 하는 환자의 치료 방법.
- TGFα-H1을 억제할 필요로 하는 환자에게 제18항에 따르는 길항제/억제제의 치료학적 유효량을 투여함을 포함하는, TGFα-H1을 억제할 필요가 있는 환자의 치료 방법.
- 제15항에 따르는 폴리펩타이드와 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
- 제15항에 있어서, TGFα-H1의 가용성 단편인 폴리펩타이드.
- 제19항에 있어서, 폴리펩타이드의 치료학적 유효량이, 폴리펩타이드를 암호화 하는 DNA를 환자에게 제공하고 생체내에 폴리펩타이드를 발현시킴으로써 투여되는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/208,008 US5633147A (en) | 1994-03-08 | 1994-03-08 | Transforming growth factor αH1 |
| US08/208,008 | 1994-03-08 | ||
| PCT/US1994/005476 WO1995024466A1 (en) | 1994-03-08 | 1994-05-12 | Transforming growth factor alpha h1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970701776A true KR970701776A (ko) | 1997-04-12 |
Family
ID=22772852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960704894A KR970701776A (ko) | 1994-03-08 | 1994-05-12 | 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5633147A (ko) |
| EP (2) | EP1063293A3 (ko) |
| JP (1) | JPH09509846A (ko) |
| KR (1) | KR970701776A (ko) |
| CN (1) | CN1087344C (ko) |
| AT (1) | ATE205254T1 (ko) |
| AU (1) | AU681406B2 (ko) |
| CA (1) | CA2184583A1 (ko) |
| DE (1) | DE69428214T2 (ko) |
| DK (1) | DK0759067T3 (ko) |
| ES (1) | ES2161246T3 (ko) |
| PT (1) | PT759067E (ko) |
| WO (1) | WO1995024466A1 (ko) |
| ZA (1) | ZA943465B (ko) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608182B1 (en) * | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
| US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
| US20020188110A1 (en) * | 1994-03-08 | 2002-12-12 | Human Genome Sciences, Inc. | Transforming growth factor alpha HI |
| US6074839A (en) * | 1994-03-08 | 2000-06-13 | Human Genome Sciences, Inc. | Transforming growth factor αHI |
| US7153827B1 (en) * | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
| US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
| ATE309360T1 (de) * | 1994-03-08 | 2005-11-15 | Human Genome Sciences Inc | Vaskularer endothelialer wachstumsfaktor 2 |
| US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
| US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6410506B1 (en) | 1995-05-19 | 2002-06-25 | Human Genome Sciences, Inc. | Transforming growth factor α HII |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US7294482B2 (en) * | 1998-11-19 | 2007-11-13 | Millennium Pharmaceuticals, Inc. | EGF-like nucleic acids |
| WO2000029438A1 (en) * | 1998-11-19 | 2000-05-25 | Millennium Pharmaceuticals, Inc. | Egf-like nucleic acids and polypeptides and uses thereof |
| US7223724B1 (en) * | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
| US20020099008A1 (en) * | 1999-04-26 | 2002-07-25 | Daniel R. Twardzik | Method for stimulating hematopoiesis using tgf-alpha |
| ATE364315T1 (de) * | 1999-04-26 | 2007-07-15 | Applied Protein Sciences Llc | Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung |
| US20020193301A1 (en) | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
| WO2001012127A2 (en) * | 1999-08-19 | 2001-02-22 | Stem Cell Pharmaceuticals, Inc. | TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| CA2407910C (en) | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
| NZ518077A (en) * | 2000-08-04 | 2003-11-28 | Human Genome Sciences Inc | Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease |
| US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
| GB0020953D0 (en) * | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| US20030170786A1 (en) * | 2001-04-13 | 2003-09-11 | Rosen Craig A. | Vascular endothelial growth factor 2 |
| WO2002083704A1 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US7402312B2 (en) * | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
| WO2002083849A2 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
| WO2004089357A2 (en) * | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
| KR101622412B1 (ko) * | 2007-10-19 | 2016-05-18 | 제넨테크, 인크. | 시스테인 조작된 항-ｔｅｎｂ２ 항체 및 항체 약물 접합체 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI890312A (fi) * | 1988-01-25 | 1989-07-26 | Oncogen | Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein. |
| US5115096A (en) * | 1988-04-15 | 1992-05-19 | Oncogen | Amphiregulin: a bifunctional growth modulating glycoprotein |
| US5256643A (en) * | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
-
1994
- 1994-03-08 US US08/208,008 patent/US5633147A/en not_active Expired - Lifetime
- 1994-05-12 DK DK94916791T patent/DK0759067T3/da active
- 1994-05-12 DE DE69428214T patent/DE69428214T2/de not_active Expired - Fee Related
- 1994-05-12 CA CA002184583A patent/CA2184583A1/en not_active Abandoned
- 1994-05-12 AU AU68350/94A patent/AU681406B2/en not_active Ceased
- 1994-05-12 JP JP7523424A patent/JPH09509846A/ja not_active Ceased
- 1994-05-12 AT AT94916791T patent/ATE205254T1/de not_active IP Right Cessation
- 1994-05-12 PT PT94916791T patent/PT759067E/pt unknown
- 1994-05-12 KR KR1019960704894A patent/KR970701776A/ko not_active Application Discontinuation
- 1994-05-12 EP EP00120470A patent/EP1063293A3/en not_active Withdrawn
- 1994-05-12 ES ES94916791T patent/ES2161246T3/es not_active Expired - Lifetime
- 1994-05-12 WO PCT/US1994/005476 patent/WO1995024466A1/en active IP Right Grant
- 1994-05-12 CN CN94195051A patent/CN1087344C/zh not_active Expired - Fee Related
- 1994-05-12 EP EP94916791A patent/EP0759067B1/en not_active Expired - Lifetime
- 1994-05-19 ZA ZA943465A patent/ZA943465B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1063293A2 (en) | 2000-12-27 |
| EP0759067A1 (en) | 1997-02-26 |
| PT759067E (pt) | 2002-02-28 |
| EP1063293A3 (en) | 2001-07-11 |
| DE69428214D1 (de) | 2001-10-11 |
| JPH09509846A (ja) | 1997-10-07 |
| WO1995024466A1 (en) | 1995-09-14 |
| EP0759067B1 (en) | 2001-09-05 |
| DK0759067T3 (da) | 2001-10-22 |
| EP0759067A4 (en) | 1997-10-22 |
| AU681406B2 (en) | 1997-08-28 |
| ZA943465B (en) | 1995-11-20 |
| ATE205254T1 (de) | 2001-09-15 |
| US5633147A (en) | 1997-05-27 |
| DE69428214T2 (de) | 2002-06-27 |
| CA2184583A1 (en) | 1995-09-14 |
| ES2161246T3 (es) | 2001-12-01 |
| CN1087344C (zh) | 2002-07-10 |
| CN1143386A (zh) | 1997-02-19 |
| AU6835094A (en) | 1995-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970701776A (ko) | 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) | |
| US6828426B1 (en) | VEGF-like factor | |
| EP0735818B1 (en) | MACROPHAGE INFLAMMATORY PROTEINS MIP-3, MIP-4 AND MIP-1gamma | |
| KR970705405A (ko) | 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides) | |
| KR970707141A (ko) | 종양 괴사 인자-감마(Tumor necrosis factor-gamma) | |
| US6566328B1 (en) | Human growth hormone | |
| US5922572A (en) | Polynucleotides encoding haemopoietic maturation factor | |
| US20020034787A1 (en) | Fibroblast growth factor-10 | |
| WO1999010364A1 (en) | Follistatin-3 | |
| RU99107759A (ru) | Применение антагонистов лептина для лечения резистентности к инсулину при диабете ii типа | |
| EP0492614B1 (en) | Epitheliocyte growth accelerator | |
| JP2007181465A (ja) | マクロファージ炎症蛋白変種をコードするポリヌクレオチド | |
| JP2005506035A5 (ko) | ||
| JPH04504105A (ja) | フォリスタチンおよびその精製法 | |
| DE777732T1 (de) | Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon | |
| RU2007110981A (ru) | Урокортин iii и его использование | |
| DE69431534T2 (de) | Bindegewebswachstumsfaktor-2 | |
| KR20040107492A (ko) | 섬유증 질병의 치료 및/또는 예방을 위한오스테오프로테게린의 용도 | |
| DE69530944T2 (de) | Keratinozyten-wachstumsfaktor 2 | |
| KR970705635A (ko) | 사람 케모킨 베타-9(Human chemokine beta-9) | |
| HK1062637A1 (en) | Use of cd26/dpp iv in the preparation of medicament for treating and/or diagnosing disease | |
| KR970701724A (ko) | 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin) | |
| CA2220854A1 (en) | Anti-ulcer composition | |
| US5504197A (en) | DNA encoding neurotrophic growth factors | |
| DE69837507T2 (de) | Humanes Hedgehog-Protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |